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OBESITY, ADIPOSITY, AND SATIETY IN MOUSE MODELS OF SMITH-
MAGENIS SYNDROME AND DUP(17)(P11.2) SYNDROME 
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A Thesis submitted in partial fulfillment of the requirements for the degree of Master’s of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director: Linda Corey 
GRADUATE PROGRAM DIRECTOR IN DEPARTMENT OF HUMAN AND MOLECULAR 
GENETICS 
 
 
 
 
 
Smith-Magenis syndrome (SMS) is a complex disorder caused by haploinsufficiency of 
RAI1 and characterized by sleep disturbances, behavioral abnormalities, mental retardation, and 
obesity in teens and adults.  Rai1+/- mice are obese after 20 weeks.  Dup(17)(p11.2) syndrome is 
a complex disorder associated with overexpression of RAI1.  A transgenic mouse model of 
dup(17)(p11.2) syndrome overexpresses Rai1 and results in a mouse that is growth delayed.  In 
order to characterize the obese phenotypes of mouse models of SMS and the role of RAI1 in 
obesity, daily food intake and serum levels of insulin, glucose, PPY, and leptin were measured; 
   
 ix 
adiposity was studied by characterizing fat deposition; and gene expression was studied in the 
hypothalamus.  These studies show that Rai1+/- mice are hyperphagic, consume more during the 
inactive light phase, and have altered satiety genes in the hypothalamus.  Adiposity studies have 
shown WT females have a higher body fat content and visceral fat proportion than males, but 
Rai1-Tg and Rai1+/- females have similar fat deposition patterns as WT males.  Hypothalamic 
gene expression studies show that many genes and pathways are affected by Rai1 and Rai1 
dosage, including many genes associated with obesity and satiety.   
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CHAPTER 1: Background and literature review 
 
 
Smith-Magenis Syndrome 
Smith-Magenis syndrome (SMS) is a complex disorder with multisystemic involvement 
caused by haploinsufficiency of RAI1, a gene located within chromosome 17p11.2
 1
.  It is 
estimated that SMS occurs in approximately one in 25,000 live births, though as awareness of 
this disorder increases and diagnoses become more accurate, this frequency will likely increase
 2
.  
SMS is characterized by sleep disturbances, self-injurious behaviors, craniofacial abnormalities, 
mild to severe mental retardation, brachydactyly, hoarse voice, and developmental delay 
 3
.  SMS 
patients also have sleep disturbances, which are attributed to an inverted circadian rhythm 
 4
. 
 
RAI1 and the Genetic Basis of SMS Retinoic Acid Induced 1 (RAI1) is the causative gene that 
is either deleted or mutated in SMS
 5, 6
.  The gene encodes a 7.6 kb mRNA from six exons  with a 
predicted protein molecular weight of 203 kD
 7
.  RAI1 contains a bipartite nuclear localization 
signal and a zinc finger-like plant homeo domain (PHD) 
 7
.  The gene also contains a CAG repeat 
region, though anticipation is not associated with SMS and pathogenic CAG repeats are not 
associated with the SMS phenotype.  Human RAI1 has 84% homology to the mouse gene and 
similar expression patterns
 7
.   
Though the cellular function is unknown, RAI1 is likely a transcription factor.  The 
protein shows a strong homology with the transcription factor TCF20, contains a bipartite  
nuclear localization signals, and ChIP-chip data has shown that it binds to the promoter regions 
   
 2 
of other genes 
 7, 8
 [Unpublished Elsea Lab data].  RAI1 mRNA is expressed ubiquitously 
throughout the body, though there is approximately three-fold higher expression in the heart and 
two-fold higher expression in the brain when compared with broad tissue expression
 7, 9
.   The 
higher level of expression was observed throughout the brain except within the corpus callosum
 
7, 8, 10
.  The corpus callosum primarily consists of glial cells and has an absence of neurons.  An 
early study concluded that RAI1 (then called GT1) was upregulated in differentiated neurons
 10
. 
SMS may be caused by either a deletion or a mutation of RAI1 
 5, 11
.  While 75% of the 
patients with an RAI1 deletion share a common deletion on 17p11.2 of approximately 3.5 Mb, 
deletions may range from ~1.5 Mb to ~9 Mb 
 12, 13
.  Patients with RAI1 mutations were observed 
to carry de novo nucleotide changes which may lead to a truncated protein, nonsense mediated 
decay of mRNA, or amino acid changes in conserved regions of the RAI1 protein 
 6
.  There have 
been no reported cases of homozygous deletions or mutations of RAI1.  
All known cases of SMS are due to either de novo mutation or deletion, though there are 
rare instances of parental mosaicism.  The SMS region 17p11.2 is prone to recombination and 
flanked by low-copy number repeats
 14
.  These repeats make the region highly prone to inter- and 
intra- chromosomal recombination.  Intrachromatid nonallelic homologous recombination 
(NAHR) results in a deletion, while interchromosomal and interchromatid NAHR typically 
results in both a deletion and a mutation
 15
.  Unequal meiotic crossovers through NAHR between 
the proximal and distal copy number repeats is the cause of approximately 70% of SMS 17p11.2 
deletions
 16, 17
.  Parental imprinting of 17p11.2 genes has not been observed 
 18
.  
There have been a broad range of clinical features reported in individuals with SMS 
including: craniofacial abnormalities, skeletal and digit abnormalities, short stature, eye 
abnormalities, ear abnormalities, chronic otitis media, organ anomalies, velopharyngeal 
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insufficiency, and hoarse voice.  Craniofacial abnormalities include: brachycephaly, a broad 
face, frontal bossing, synophrys, hypertelorism, upslanting eyes, midface hypoplasia with a 
depressed nasal bridge, a tented upper lip, prognathism, low-set or abnormally shaped ears, 
dental anomalies, cleft lip or palate, and eye abnormalities
 11, 19, 20
.  Skeletal and digital 
abnormalities include: brachydactyly, persistent fetal finger pads, fifth-finger clinodactyly, 2/3 
toe syndactyly, scoliosis, vertebral anomalies, and polydactyly 
 1, 2, 21
.   Chronic otitis media and 
sensorineural hearing loss was observed in 68% or patients 
 11
.  Heart and renal defects, and cleft 
lip/palate are highly variable in SMS patients.  It is hypothesized that these phenotypes may be 
due to heterozygosity of genes other than RAI1 in the 17p11.2 region 
 5
.  Brain imaging and 
autopsy reports of SMS patients have revealed cases of ventriculomegaly, enlarged cisterna 
magnum, patial agenesis of vermis, frontal lobe calcification, Joubert syndrome, and decreases in 
gray matter of the incula and lenticular nucleus
 1, 2, 22, 23
.  Seizures are seen in approximately 30% 
of patients 
 2, 11
.  
Most SMS patients have mild to severe mental retardation, including delayed motor and 
speech milestones.  IQs may range from 20-78 for 17p11.2 deletion cases
 2
.  Some patients have 
been classified as low normal as young children but considered to have mild mental retardation 
by adulthood
 17
.  
 
Behavioral Abnormalities Circadian Rhythm  Behavioral phenotypes are observed in the 
majority of SMS cases, with 92-98% exhibiting self-injurious behavior 
 24, 25
.  Self-injurious 
behavior may include: hand-biting, hitting, self-pinching, scratching, picking at sores, head-
banging, pulling at nails, and polyembolokoilamania  1, 26.   Stereotypies, short attention span and 
poor short term memory have also been observed 27, 28.  Some SMS patients have also been 
diagnosed with ADHD, OCD, autism, and hyperactivity 29, 30. 
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Sleep disturbances are reported in 75-100% of SMS patients 11, 31.   Hypersomnolence is 
observed in infants, while older children have difficulties falling asleep, reduced night sleep, short 
sleep cycles with nocturnal and early-morning awakening, and excessive daytime sleepiness 31, 32, 33, 
34.  These patterns are likely due in part to inverted circadian rhythm of melatonin, though other 
circadian rhythm hormones (cortisol, growth hormone, and prolactin) are not affected  30, 33.  
Melatonin is a ubiquitous hormone that regulates sleep induction through vasodilation in the 
extremities and seasonal phase shifting  35, 36.  Melatonin is synthesized in the pinealocytes of the 
pineal gland via the acetylation of serotonin, which is then converted to its active form via 
hydroxyindole O-methyltransferase.  Photosensitive melanopsin expressing retinal ganglion cells 
signal the suprachiasmatic nucleus (SCN) via the retinohypothalamic track 35.  The SCN then 
releases an inhibitory signal to the paraventricular nucleus, which stimulates the production of 
melatonin in the pineal gland.  Circulating melatonin has a half-life of 2-20 min and is metabolized 
in the liver  35, 37.  In a normal circadian rhythm, melatonin plasma levels rise a few hours before 
sleep is peaks in the middle of the night.  In SMS patients, melatonin plasma levels are high during 
the day but low at night.  This altered melatonin pattern has been treated with !-adrenergic 
antagonists during the day and melatonin administration during the night.  The combination 
treatment was observed to decrease daytime sleepiness, reduce the incidence of tantrums, and 
increase concentration.  There were no cognitive improvements and problematic behavior decreased 
but was not completely eliminated  30.  
 
Obesity and SMS In infants with SMS, there are feeding difficulties and hypotonia.  In teens 
and adults, truncal obesity is common 
 17
. The majority of SMS patients become obese by the 
time they reach adulthood, with an increased prevalence of hypercholesterolemia
 38
.  A study of 
54 children found that by age 12, SMS females were in the 90th weight percentile and SMS 
males were in the 90th percentile by age 14
 38
.  An earlier study found that a majority of SMS 
patients had lipid values greater than the 95th percentile for age and gender for at least one or 
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more of the following: total cholesterol, triglycerides, and/or low density lipoproteins
 39
.  SMS 
patients may develop an obsessive fixation on food and problems regulating intake, which may 
require caretakers to regulate intake or lock up food.   
 
Dup(17)p11.2 Syndrome 
A different genetic disorder, dup(17)(p11.2) syndrome, sometimes referred to as Potocki-
Lupski syndrome, results in subtle craniofacial abnormalities, growth delay in childhood, heart 
defects, mild to severe mental retardation, lean body mass, and hyperactivity
 40, 41
.  There are no 
observed circadian rhythm anomalies in dup(17)(p11.2) syndrome
 42
.   All individuals with this 
disorder have 3 copies of RAI1 
 42, 43
.  While the incidence of dup(17)(p11.2) syndrome is 
unknown, it is suspected to have a similar incidence to SMS, the reciprocal deletion syndrome
 43
. 
 
SMS and dup(17)p11.2 Mouse Models 
In a model of SMS, heterozygous Rai1-knockout mice were created on a mixed 
background and backcrossed to C57Bl/6. These mice are slightly smaller than their wild-type 
littermates at 5 weeks, comparable to control mice at 10 weeks, and overweight by 20 weeks
 9
.  
They also have an altered sleep cycle, behavioral abnormalities, variable penetrance of 
craniofacial defects, and reduced fertility 
 44
 [Elsea lab unpublished data].  These mice were 
created by an insertion of a Escherichia coli lacZ coding sequence
 
and a neo
R
 expression cassette 
which deleted 3910 bp nucleotides of the coding region of exon 2 in 129SvEv/Brd embryonic 
stem cells.  These clones were inserted into C57BL/6Tyr
c-Brd 
blastocysts
 9
.  This insertion 
truncates the Rai1 protein, removing nuclear localization signals and the PHD domain, producing 
an effectively null allele
 9
.  Animals that are homozygous for the Rai1 mutation are embryonic 
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lethal by approximately 16 days post coitum 
 9
.   There is a distorted transmission of the mutant 
Rai1 allele, with litters containing ~13% Rai1+/- pups compared to ~50% Mendelian 
expectations
 45
  
In order to evaluate the effects of overexpression of RAI1 and to determine how it 
contributes to the human dup(17)(p11.2) syndrome phenotype, a transgenic mouse model was 
created that overexpresses Rai1
 42
.  Both hemizygous (with 2 copies of the BAC transgene) and 
homozygous (4 copies of the BAC transgene) Rai1 overexpressing mice in a C57Bl/6 
background have been evaluated
 42
.  Previous members of the Elsea lab reported growth 
retardation in Rai1-transgenic mice up to 20 weeks when compared with wild-type littermates
 42
.  
These mice also have poor maternal behavior, have an abnormal gait, display behavioral 
abnormalities, and are hyperactive
 42
. 
 
Summary 
RAI1 duplication and deletion syndromes are multisystemic and complex.  This study 
aims to focus on the obesity and growth phenotypes associated with Smith-Magenis Syndrome 
and dup(17)(p11.2) syndrome.  Both the overexpression and underexpression of Rai1 in mice 
produces phenotypes similar to those observed in dup(17)(p11.2) syndrome and SMS patients, 
making these mice ideal to study the effects of Rai1 dosage.  In order to determine the role of 
Rai1 on growth and obesity, we have conducted studies focused on feeding behavior, adiposity, 
and hypothalamic expression.  We have conducted an anonymous survey to characterize the fat 
deposition patterns in patients with SMS and dup(17)(p11.2) syndrome.  These studies reveal 
that Rai1 plays a role in feeding behavior and timing, fat distribution, and the expression of 
genes relating to satiation and obesity within the hypothalamus.  A more thorough understanding 
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of the role of Rai1 in growth and obesity will allow us to understand the comorbidities that may 
affect patients of RAI1 syndromes and provide insight into the complex biology of obesity, 
growth, and behavior.  
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CHAPTER 2: Determination of feeding and satiation in Rai1+/- and 
Rai1-Tg mice 
 
 
INTRODUCTION 
Simulation of human conditions in animals can be used to identify biological mechanisms 
that contribute to behavior in known disorders.  Mouse models are particularly useful for 
studying human genetic disorders.  Transgenic mice and gene targeting in mice allow for the 
study of dosage effects of genes, because genes may be added to mimic overexpression, and 
“knocked-out” to mimic under expression or null expression.  Rai1-Tg mice overexpress Rai1, 
while Rai1+/- mice have reduced expression-- modeling dup(17)(p11.2) syndrome and Smith-
Magenis syndromes, respectively.   
In Smith-Magenis syndrome, obesity is a noted phenotype in teens and adults, and 
hyperphagic behavior is observed
 11, 27, 38
.  Case studies in SMS patients have revealed obsessive 
preoccupation with food and hoarding
 11
.  Likely due to circadian rhythm abnormalities, night 
eating is also observed in SMS patients.  Noted therapies for patients with SMS include strict 
dietary control and restricting food access by locking cabinet or kitchen doors.   
Mouse models have been useful in identifying genetic factors that contribute to 
hyperphagic behavior and obesity in humans disorders, including Bardet-Biedl syndrome
 46
, 
Prohormone convertase 1 (Pc1) deficiency
 47
, leptin deficiency
 48
, and brain-derived neurotrophic
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factor (Bdnf) haploinsufficiency
 49
.  Circadian rhythm abnormalities have also been studied in 
mice, including Clock mutation
 50
, Baml1 mutation
 51
, and the Period (Per) genes
 52
.  These 
studies demonstrate that circadian rhythm is essential for normal behavior, feeding behavior, 
blood pressure, weight, and fertility.   
To characterize feeding in these mouse models, we conducted studies to determine 
overall food consumption, the proportion of food consumed during the active phase, and serum 
level analysis of satiety hormones. Overall food consumption can be used to determine 
hyperphagia.   The amount of food consumed during the active phase can be used to determine if 
these animals are modeling “night eating” or eating during the inactive phase.  Fasting studies 
and serum level studies can be used to determine the efficiency of the satiation response after a 
period of induced hunger.  These studies may lead to more comprehensive understanding of the 
behavioral phenotypes of Smith-Magenis that contribute to obesity.   
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MATERIALS AND METHODS 
Breeding and maintenance.  Rai1+/- and Rai1-Tg mice were bred with C57Bl/6J mice.  When 
breeding, Rai1+/- and Rai1-Tg males were in isolated cages with one or two C57Bl/6J females, 
while Rai1+/- and Rai1-Tg females were in isolated cages with one C57Bl/6J male.  Due to the 
poor maternal behavior of the transgenic females, nontransgenic or  C57Bl/6J females were 
added 2-3 days prior to birth
 42
.  Pups were weaned, tail clipped, tagged, and separated by sex at 
3 weeks.  One to five mice were housed by sex and age in a cage.   
Mice had access to water and a standard diet of high fat Lab Diet 5P06 and low fat Tekland 
LM-485 7012 food ad libitum.  A constant temperature (21°C), humidity (40%), and automatic 
twelve hour light/dark cycle were maintained at all times.  All tests were preformed during the 
light portion of the cycle except for light phase feeding studies, which were done using a red 
light to avoid altering the dark period.  All animals were housed in compliance with the 
guidelines of the IACUC at Virginia Commonwealth University.  All procedures were submitted 
and approved by the IACUC at Virginia Commonwealth University.  
 
Genotyping.  The genotypes of the mice were confirmed using PCR analysis on DNA prepared 
from mouse tails using a salt extraction method and the Qiagen miniprep isolation protocol.  The 
genotypes of Rai1-Tg mice were confirmed using unique BAC-end specific primers reported in 
Girirajan, 2008.  The genotypes of the Rai1+/- were confirmed using target allele and wild type 
primers reported in Bi et al., 2005.  
 
Isolated feeding studies.  In order to examine the average daily food consumption, males and 
females of Rai1-Tg and Rai1 +/- genotypes were placed in isolated cages and given a pre-
   
 11 
weighed amount of high fat food.  Food was weighed every 24hrs for 5 days.  Evaluations were 
preformed at 5, 10, 15, 20, and 25 weeks.  Data were compared with sex and age matched wild-
type littermates.  These methods were developed based on techniques reported in the literature 
regarding mouse feeding behavior
 46, 53, 54
.   
 
Light phase and fasting feeding studies.  To determine the effect of Rai1 on night eating and 
satiation, male mice of each genotype (Rai1-Tg, Rai1+/-, and wild-type) were placed in isolated 
cages with a predetermined amount of high fat food and an unlimited amount of water.  Food 
was weighed every 12 hrs for 3 days.  Night measurements were taken using a red lamp.  To fast 
animals, all food was removed for 24 hrs and animals were placed in a new cage to prevent 
hoarding.  After 24 hrs a predetermined amount of food was returned at the beginning of the light 
phase.  Food weight measurements were taken every 2 hrs for 6 hours after the fast.  
Measurements continued every 12 hrs for 3 days.  These evaluations were preformed at 15 and 
20 wks of age.  These methods were developed based on techniques found in the literature 
regarding mouse night eating behavior
 55
. 
 
Blood glucose.  Blood was drawn from a needle prick on the end of the tail and measured using 
capillary test strips and an Easy Pro glucometer.  Glucose tests were done in duplicate at 20 
weeks to ensure accuracy.  
 
Serum analysis.  Blood was collected from animals via cardiac puncture after CO2-induced 
unconsciousness.  Serum was separated by allowing the blood to clot for twenty minutes 
followed by centrifugation at 2000 xg for 10 minutes.  For samples that required fasting 
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conditions (leptin, insulin, PYY), blood was collected from the “facial vein” under general 
anesthesia with isofluorene after the previously described fasting studies.  ELISA tests were 
performed at the University of Cincinnati Mouse Phenotyping Core.  
 
Ketone analysis.  Animals were isolated in small container with no bedding until they urinated.  
After the animals were returned to their normal cages, an Alva Thinz Metabolism Strip #25 was 
dipped into the urine.   
 
Statistical Analyses.   All statistical methods were conducted in JMP software.  Mean food 
consumption at 5, 10, 15, 20, and 25 weeks were compared using pooled data from 12 different 
isolated feeding studies that depended on genotype and age availability. These data were 
compared among the 3 genotypes (WT, Rai1+/-, and Rai1-Tg) using ANOVA.  
Food intake after the 24 hr fast (taken at 2-48hrs) was evaluated using repeated measures 
ANOVA, with effects for individual mouse, genotype, time point, and group time interaction. 
These data were also evaluated separately for each time point using ANOVA.  
The average proportion of food consumed at night was evaluated using repeat measures 
ANOVA.  
   
 13 
RESULTS 
Isolated Feeding Studies.  The feeding behavior of Rai1+/-, Rai1-Tg, and wild-type mice was 
observed using isolated feeding studies as described in the methods.  These studies were sex and 
age matched at 5, 10, 15, 20, and 25 weeks for Rai1-Tg and wild-type mice.  Rai1+/- mice were 
not included in all studies due to their drastically reduced fertility.  Male Rai1+/- were studied at 
15 and 20 weeks of age.  A two way ANOVA analysis of the average amount of food per day (g) 
over the weight of the mouse (g) was used to compare each group.  Food consumption indicates 
that there is no difference between wild-type and Rai1-Tg mice food intake at 5, 10, 15, 20, or 25 
weeks.  Rai1-Tg mice did not consume more or less than their wild-type littermates (Fig. 1A, 
1B).  However, using pooled data from isolated feeding experiments, we found that Rai1+/- 
male mice were hyperphagic at 15 weeks (p=. 0159) and 20 weeks (p<0.05) (Fig. 2A, 2B).  
 
Light phase and fasting feeding studies.  To determine if the mice were eating during the rest 
cycle (for nocturnal mice, this is the light phase of the 12 hr dark/light cycle), isolated feeding 
studies were conducted by taking measurements every 12 hours, shortly after the beginning of 
each light and dark phase.  Male Rai1+/-, Rai1-Tg, and wild-type littermates were studied at 15 
and 20 weeks of age.  A two way ANOVA analysis of the proportion of total food consumed 
during the dark cycle was used to compare each group.  At age 15 weeks, Rai1+/- mice 
consumed a significantly higher proportion of their food during the (inactive) light phase than 
wild-type mice (p=.0191) (Fig. 3A).  At 20 weeks, this pattern was observed with Rai1+/- mice 
consuming ~57% of their food during the dark phase and wild type mice consuming ~65% of 
their food during the dark phase, though it did not achieve significance (Fig. 3B).   
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Figure 1:  Food consumption in Rai1-Tg male and female mice.  A. Daily food intake (g) over 
body weight (g) for male mice ages 5-25 weeks.  B. Daily food intake (g) over body weight (g) 
for female mice ages 5-25 weeks.  Data were analyzed using a two way ANOVA for genotype, 
gender, and interaction (n!5 of each gender and genotype). Graphs indicate mean±SEM.  
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Figure 2:  Food consumption in Rai1+/-, Rai1-Tg, and Wt mice.  A. Daily food intake (g) 
over body weight (g) for male mice at age 15 weeks.  B. Daily food intake (g) over body weight 
(g) for male mice at age 20 weeks.  Data were analyzed using a two way ANOVA for genotype, 
gender, and interaction (n!5 of each gender and genotype).  Graphs indicate mean±SEM. 
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Figure 3:  Food consumed during the dark (active) phase.  A. Rai1+/- mice eat significantly 
less of their daily intake during the dark phase. (p<.05) B.  Rai1+/- mice eat less than wild-type 
mice at night. However these data do not achieve significance.  
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Hunger was induced using a 24 hr. fast to test satiety.  Male mice of each genotype were 
isolated in cages with no access to food.  After 24 hours, serum was collected, blood glucose 
levels were assessed, and food was returned.  When food was returned, measurements of food 
consumption were taken ever 2 hours for the first 10 hours, and every 12 hours afterwards.  For 
the first 12 hrs after fasting conditions, Rai1+/- mice consume significantly more food than wild-
type mice (p=.0023) (Fig. 4A).  Also, Rai1+/- mice were observed to have a delayed satiation 
response.  Rai1+/- consume significantly more food than wild-type mice at 36 hours post fast 
(p=.0473) (Fig. 4B).  Blood glucose tests did not indicate elevated fasting glucose levels in either 
Rai1-Tg or Rai1+/- mice (Fig. 5).   
 
Urine Ketone Test.  In order to determine if mice had diabetic ketoacidosis, urine was tested for 
ketones using urinalysis dip strips.  Non-fasting wild-type, Rai1-Tg, and Rai1+/- mice showed 
no evidence of ketone bodies in urine.  
 
Serum Analysis.  To determine the possible effects of the satiety signals leptin and PYY, and 
insulin on the phenotype of these mice, isolated serum samples from each genotype were 
evaluated at the University of Cincinnati Mouse Phenotyping Core (Fig. 6).  Insulin levels were 
low in the Rai1-Tg mice and unaltered in the Rai1+/- mice.  Leptin levels were high in the 
Rai1+/- mice.  PYY was also elevated in the Rai1+/- mice, but not significantly.  
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Figure 4:  Food intake after 24 hr fast.  A. Immediately after the fast, food consumption was 
measured at 2 hr intervals. At 8 and 12 hrs, Rai1+/- mice consume more food than Rai1-Tg or 
wild-type mice.  B. For two days after the fast, food intake was measure every 12 hrs.  At 12 and 
36 hours after the fast, Rai1+/- mice consume more of their food than wild-type mice.  The large 
SEM for Rai1+/- mice at 48 hrs indicates delayed satiety in only one of the mice; this did not 
achieve statistical significance.  Graphs indicate mean±SEM. 
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Figure 5:  Fasting blood glucose measurements in mice.  A.  At age 15 weeks.  The large 
SEM observed is within normal range for fasting glucose level and is a consequence of our low 
sample size B. At age 20 weeks.  There was no observed difference in fasting blood glucose in 
any of the genotypes. Graphs indicate mean±SEM. 
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Figure 6: Fasting serum level analysis.  Fasting serum levels of mice for insulin, PYY,  and 
leptin.  Data indicate hypoinsulinemia in Rai1-Tg mice, a possible increase in PPY in Rai1+/- 
mice, and increased leptin in Rai1+/- mice.  *p<.05.  Graphs indicate mean±SEM. 
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DISCUSSION 
These data show that Rai1+/- mice are hyperphagic and fasting studies indicate that these 
mice have a delayed satiation response after induced hunger.  These mice do not exhibit 
glucosuria, increased insulin, or have an elevated fasting glucose level, so it is unlikely that they 
have some type of insulin resistance.  The elevated leptin and PYY levels in these mice indicate 
that the gut satiety signals are high.  If leptin and PYY signaling were functioning as we would 
expect, Rai1+/- mice with an increased serum leptin would have a sensitive satiation response 
and possibly hypophagia and resistance to obesity
 56, 57
.  However, high serum leptin has been 
identified as an early indication of adult-onset obesity in children
 58
.  Taken together, the obesity 
observed in these mice is likely due to hyperphagia caused by a muted satiation response 
possibly due to leptin resistance
 59
.   
Rai1-Tg mice are not hyperphagic and do not have a delayed satiation response.  These 
mice do have hypoinsulinemia.   However, these mice do not have an elevated fasting blood 
glucose.  Taken together, these results may indicate high insulin sensitivity.   
Light phase studies may indicate increased feeding activity during the day in Rai1+/- 
mice, which may mimic night eating behavior in humans.  Unfortunately the variability within 
the sets of mice and lack of significance at 20 weeks indicate that, while promising, the incidence 
of night eating within Rai1+/- mice will need to be confirmed with a larger sample of mice.  
Night eating, increased leptin, and obesity have also been observed in the mice deficient in the 
prostaglandin E2 signaling gene, EP3R
 55
.  The similarity of these phenotypes could indicate a 
role of adipose hormone signaling in the phenotype of Rai1+/- mice. 
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CHAPTER 3: Adiposity in Mouse Models of RAI1 Syndromes 
 
 
INTRODUCTION 
Clinician and geneticists’ notes indicate truncal obesity in individuals with Smith-
Magenis Syndrome
 17
.  SMS patients also have an increased incidence of hypercholesterolemia, 
which can contribute to heart disease
 39
.  This is of particular interest due to current research that 
demonstrates increased stores of visceral fat may be pathogenic for co-morbidities of obesity 
including: cardiovascular disease, insulin resistance, hypertension, and metabolic syndrome
 60
.  
Adiponectin, an adipocytokine, has been associated with juvenile onset obesity and increased 
visceral obesity
 61
.   
In order to characterize adiposity in SMS and dup(17)(p11.2) syndrome, we conducted an 
anonymous online survey to assess body shape, determined fat deposition patterns in Rai1 mouse 
models, and measured serum adiponectin levels in mice.  The anonymous online survey can be 
used to determine body shape, including truncal obesity, in patients with SMS and 
dup(17)(p11.2) syndrome.  Body fat deposition in mouse models can be used to assess visceral 
fat deposition in mouse models of SMS and dup(17)(p11.2) syndrome.  Investigation of fat 
deposition patterns and adiponectin levels in Rai1 mice may help to characterize the cause and 
pathogenicity of the truncal obesity observed in Smith-Magenis patients.   
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MATERIALS AND METHODS 
Survey.  An anonymous online survey was designed to assess body shape in patients with RAI1 
deletions, mutations, and duplications.  The survey was distributed to caregivers of RAI1 patients 
via the SMS support website PRISMS, the SMS Yahoo! Listserv, and the dup(17)(p11.2) 
syndrome Yahoo! Listserv.  The survey assessed body type by asking the caregiver to select a 
description which best described the fat deposition pattern for their child.  The survey included a 
cartoon depiction of the type of fat deposition as well as a written description such as “My 
son/daughter tends to store extra weight on arms, legs, hips, and buttocks.  Very little weight is 
stored around the waist.” 
The survey addressed the patient’s backgrounds and included questions regarding gender, 
age, height, weight, formal diagnosis by a geneticist, and the most recent time the patient saw a 
physician.  The patient’s clinical history of diabetes, high cholesterol, and high triglycerides were 
also assessed.  Weight percentile was determined using BMI and CDC growth assessment charts 
for children ages 2 to 20 years.  See Appendix 1 for the survey measure. 
 
Fat Distribution Patterns in Rai1 mice.  Fat distribution in Rai1+/- mice and Rai1-Tg mice 
was determined via dissection.  Male and female mice of each genotype were selected at ~30 
weeks, weighed, and euthanized via a CO2 chamber.  Intra-abdominal fat pads (gonadal, 
retroperitoneal, and mesenteric) and subcutaneous fat pads (dorsal, inguinal and groin) were 
collected via dissection and weighed
 55
.  Measurements of both abdominal and subcutaneous fat 
pads were combined to determine the amount of total fat collected.  
 
   
 24 
Serum Analysis.  Blood was collected from animals via cardiac puncture after CO2-induced 
unconsciousness.  Serum was separated by allowing the blood to clot for 20 minutes followed by 
centrifugation at 2000 x g for 10 minutes.  ELISA tests for blood serum  levels of adiponectin 
were performed at the University of Cincinnati Mouse Phenotyping Core. 
  
Statistics.  Fat distribution p-values were determined using a one-way ANOVA fit model with 
corrections for sex, genotype, and weight.  All tests were done using JMP statistical software.  
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RESULTS 
 
Body shape and adiposity in RAI1 patients.  An online survey of RAI1 patient caregivers was 
used to corroborate clinician’s notes regarding abdominal obesity in SMS patients (Table 1).  
From a sample of 65 responses, there were 38 individuals with Smith-Magenis syndrome (36 
with a RAI1 deletion and  2 individuals with a RAI1 mutation) and 12 individuals with 
dup(17)(p11.2) syndrome.   
In SMS individuals with a RAI1 deletion, the mean age was 13.5 years (range = 3 to 51), 
and 58% were female.  Of these patients, three were diabetic, five had high cholesterol, and four 
had high triglycerides.  In the SMS deletion group, 41% had a BMI in the 95
th
 percentile or 
higher for their age and sex.  Seventeen individuals (45%) were described as having mostly 
truncal obesity with excess weight stored “around the waist and stomach areas- very little stored 
around the legs and buttocks”.  Of these seventeen individuals, 13 (76%) were female.  
In dup(17)(p11.2) syndrome individuals, the mean age was 6.5 years (range=2 to 12), and 
33% were female.  None of these individuals were diabetic or had high cholesterol or 
triglycerides.  In the dup(17)(p11.2) syndrome group, two (16%) had a BMI in the 95
th
 percentile 
or higher for their age and sex.  Nine individuals (75%) were described as “very thin, has no 
excess weight, [and] veins are visible through the skin.”  
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Table 1: Summary of Patient Fat Distribution Survey 
 
SMS Dup17p11.2 
n 38 12 
Mean age 13.5±9.0 6.5±3.0 
Range 3-51 2- 12 
Sex 42% M/ 58% F 67% M/33% F 
BMI 23.6±7.9 16.9±4.4 
>95 percentile 41.00% 16.70% 
>95 percentile; >9 years 50% 0% 
Diabetes 3 0 
Hypercholesterolemia 5 0 
High triglycerides 4 0 
Subcutaneous only 0 0 
Truncal only 9 (7f) 0 
Uniform distribution 10 2 
No excess weight 3 9 
Excess uniform distribution 8 0 
Fat Distribution 
Excess truncal only 8 (6 F) 1 
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Fat distribution patterns in Rai1 mice.  Fat distribution was analyzed by dissection on Rai1-
Tg, Rai1+/-, and wild-type mice.  Rai1-Tg and wild-type mice were analyzed at ~30 weeks, 
though Rai1+/- mice were analyzed at 45+ weeks due to problems procuring new mice.  There 
was no difference in body weights or the amount of total fat extracted between sex-matched 
Rai1-Tg and wild-type mice (Fig. 7A, Fig. 7B).  However, there was a significant difference in 
the amount of abdominal fat in Rai1-Tg and Rai1+/- mice compared to wild-type mice (Fig. 8).  
Wild-type male mice have a higher proportion of abdominal fat than subcutaneous fat, while 
Rai1-Tg and Rai1+/- have higher proportions of subcutaneous fat (Fig. 8A).  In females, the 
patterns are reversed.  Wild-type female mice have a higher proportion of subcutaneous fat than 
abdominal fat, while Rai1-Tg and Rai1+/- have higher proportions of abdominal fat (Fig. 8B).   
 To determine that the previous results were attributable to the genotypes and not the diet 
or age of the mice, the same studies were performed on 14 week old male littermates fed a 
regular chow rather than a high fat chow.  The results showed the 14 week old Rai1-Tg mice also 
have a higher proportion of subcutaneous fat than their wild-type littermates, indicating diet and 
age were not a factor (Fig. 9).  
 
Blood serum adiponectin levels.  To determine the possible effects of the fat secreted hormone 
adiponectin on the phenotype of these mice, isolated serum samples from each genotype were 
evaluated at the University of Cincinnati Mouse Phenotyping Core.  There was no significant 
difference in serum levels of adiponectin in Rai+/- or Rai-Tg mice when compared to wild-type 
adiponectin levels (Fig. 10). 
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Figure 7: Body weights and total fat collected in Rai1-Tg mice.  A. Comparison of body 
weights at the time of study between sex matched Rai1-Tg and wild-type mice.  There was no 
observed difference between genotypes. B. Comparison of total fat extracted from sex matched 
Rai1-Tg and wild-type mice during the fat deposition study.  There was no observed difference 
between genotypes. Total fat was defined as the weight of the sum of all extracted fat over body 
weight. Graphs indicate mean±SEM. 
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Figure 8:  Fat distribution patterns in Rai1 mice.  A. Fat distribution in males.  Rai1+/- and 
Rai1-Tg mice have a significantly lower proportion of visceral fat than wild-type mice.  B. 
Females have an opposite fat deposition pattern compared to males.  Female WT mice have a 
lower proportion of visceral fat than males, while Rai1+/- and Rai1-Tg mice have a significantly 
higher proportion of visceral fat than wild-type female mice.  (* p <.05, **p <.01, *** p <.001)  
Graphs indicate mean±SEM. 
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Figure 9:  Fat distribution patterns of male Rai1-Tg mice at 14 weeks on a low fat diet.  
Rai1-Tg mice (n=2) have a significantly lower proportion of visceral fat than their wild-type 
littermates (n=2).  (p<.05) Graphs indicate mean±SEM. 
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Figure 10: Blood serum levels of adiponectin.  There was no significant difference in the blood 
serum levels of adiponectin in any of the genotypes.  Graphs indicate mean±SEM. 
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DISCUSSION 
Population estimates from the Centers for Disease Control show that the prevalence of 
obesity at ages 6-11 is 17% and at ages 12-19 is 17.3%.  Based on our sample, the prevalence of 
obesity in SMS patients at ages 9 and up is 50%.  Edelman, et al. (2007) previously reported a 
higher incidence of obesity in RAI1 mutation patients, likely due to hyperphagia
 11
.  A 
disproportionate number of SMS females also have a high reported abdominal fat deposition 
pattern.  Visceral obesity has a much higher prevalence in males 
 62
.  Visceral obesity is 
associated with an increased risk for obesity comorbidities, including hypertension, high 
triglycerides, and diabetes.  The incidence of diabetes, hypercholesterolemia, and hypertension is 
not higher for individuals with SMS when compared to the general population.  This may be due 
to a lack of testing in younger patients or due to a lack of data on older SMS individuals.   
When we evaluate the fat distributions in Rai1+/- and Rai1-Tg mice, we find similar 
changes in body fat distribution.  Rai1+/- and Rai1-Tg females have higher proportions of 
abdominal fat than wild-type females, while Rai1+/- and Rai1-Tg males have less abdominal fat 
than wild-type males.  This is similar to the large proportions of SMS females with reported 
abdominal adiposity.   
Adiponectin negatively correlates with high visceral fat deposition, insulin resistance, 
diabetes
 
mellitus, coronary heart disease, and metabolic syndrome
 63, 64, 65, 66
.  Serum adiponectin 
levels in Rai1+/- or Rai1-Tg mice do not decrease and the serum results in Chapter 2 do not 
indicate diabetes.  These data indicate that RAI1 haploinsufficiency contributes to early-onset 
obesity and increased visceral fat deposition in females, but does not increase incidences of 
visceral fat associated insulin resistance and diabetes.   
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CHAPTER 4: Microarray analysis of Rai1 Mice Hypothalami 
 
 
INTRODUCTION 
The alteration in dosage of transcription factors may have widespread effects on other 
genes.  The Rai1 protein contains a bipartite nuclear localization signal and a PHD/zinc finger 
domain 
 7
.  It also has a strong homology to the transcription factor TCF20
 8
.  Given these 
characteristics, we believe that the RAI1 protein is a transcription factor and that variation in 
dosage of RAI1, such as those seen in dup(17)(p11.2) syndrome and Smith-Magenis syndromes, 
may contribute to the complexity of these disorders.   
The hypothalamus is a region of the brain involved in satiety
 67, 68, 69, 70
, thirst
 71, 72
, 
thermoregulation
 73, 74
, and circadian rhythm
 75
.  Alterations of gene expression in the 
hypothalamus, including Bdnf, Npy, and estrogen receptor genes, can affect feeding and 
hyperphagia-induced weight gain in mice.  In order to evaluate the downstream effects of Rai1 
dosage alterations in mice, we choose to evaluate gene expression levels in the mouse 
hypothalamus. Whole genome hypothalamic expression patterns may indicate obesity associated 
genes that are altered when Rai1 is overexpressed in Rai1-Tg mice or underexpressed in Rai1+/- 
mice.  These studies may indicate downstream pathways which affected by Rai1 expression that 
contribute to the phenotypes of SMS or dup(17)(p11.2) syndrome.  
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MATERIALS AND METHODS 
Hypothalamus Isolation- Male and female 30 week old wild-type and Rai1-Tg mice were 
euthanized by CO2 chamber.  Rai1+/- mice were 52+ weeks at time of death and tissue 
collection.  Hypothalami were immediately extracted from mouse brains and stored at -80°C.  
 
RNA Isolation- RNA was isolated using the Trizol Reagent/chloroform isolation method.  The 
quality of the isolated RNA was determined using a 260/280 absorbency ratio and assessed using 
a Thermo Scientific Nanodrop 1000.  Equal quantities of RNA were pooled for a wild-type 
sample (6 male mice) and a Rai1-Tg sample (5 male mice).  Only two 52+ week male mice were 
available for the Rai1+/- sample.  These mice were used as individual samples so that the data 
may be combined with future microarray data.  
 
Microarray- Microarray hybridization was performed in the Massey Cancer Center Nucleic 
Acids Research Facility, DNA Microarray Core using an Illumina MouseWG-6 v2.0 expression 
beadchip.  The array was read using an Illumina BeadScan confocal scanner and analyzed by 
Illumina's BeadStudio software. 
 
Microarray Data Analysis- Using the Illumina BeadStudio Software, differential analysis was 
performed between the Rai1+/- and wild type genotypes and the Rai1-Tg and wild-type 
genotypes.  Data were normalized using the quantile method.  Differential P-values were 
determined using the Illumina custom analysis.  The software was also used to calculate a false 
discovery rate (FDR) and to adjust p-values accordingly.  Detection p-values <.05 were used to 
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determine which probes were detected.  Heat maps to visualize gene distribution were created 
using JMP statistical software.  
 
Pathway Analysis- Pathway analysis was done using the Ingenuity Pathway analysis for gene 
and protein interaction.  Significant interactions were determined using the Ingenuity Pathway 
Knowledge Base and a Fisher’s exact test for significance for each pathway and biological 
function.  
 
Real-time quantitative PCR- RNA from hypothalami from male and female mice of each 
genotype was isolated using the Trizol reagent/chloroform method and quality assessed by 
nanodrop.  Some individual hypothalamus samples that were used in the pooled samples in the 
microarray were analyzed using Q-PCR.  cDNA extraction was performed using 4 "g of RNA, 
Invitrogen Superscript 2 reverse transcriptase and random primers according to the 
manufacturer’s instructions.  ABI Taqman probes for mouse mRNA expression were used to 
detect gene expression for Bdnf, Cck, Npy, and Rai1.  All samples were run in triplicate in a 10 
"L reaction on a ABI Prism 7500 Fast System with Gapdh as an endogenous control.   
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RESULTS 
Hypothalamic gene expression altered by Rai1 dosage.  Using a microarray to test the global 
expression of genes in the hypothalami of Rai1+/- and Rai1-Tg mice, we found that Rai1+/- 
mice express a 1.6-fold decrease of Rai1 in the hypothalamus compared to wild-type mice, while 
Rai1-Tg mice have a 1.2-fold increased expression of Rai1.  These values are muted compared to 
previous data which suggest Rai1+/- mice express less than ~50% Rai1 than wild-type and Rai1-
Tg mice express a 1.5 fold increase in Rai1 over wildtype 
 42, 9
.  Q-PCR was used to confirm Rai1 
expression.  
 To identify genes differentially expressed from wild-type, we used the Illumina Custom 
test for differentiation, which is more useful at estimating variance within a small sample size 
than the Wilcoxon signed-rank test or Student’s t-test.  Our analysis detected 23,000 probes for 
16,000 genes. 
In Rai1+/- mice, 92 genes were significantly upregulated (p < .05); using a higher 
stringency (p < .01), 5 genes were significantly upregulated.  In Rai1+/- mice, 397 genes were 
significantly downregulated (p < .05), while using a higher stringency (p < .01), 68 genes were 
significantly downregulated.  The top genes downregulated by reduced Rai1 expression by 
differential p-value and fold change are shown in Table 2.  
In Rai1-Tg mice, 1593 genes were significantly upregulated (p < .05).  Using a higher 
stringency (p < .01) to determine differential expression, 899 genes were significantly 
upregulated.  In Rai1-Tg mice, 1462 genes were significantly downregulated (p < .05).  Using 
the more stringent criteria (p < .01), 864 genes were significantly downregulated.  The top genes 
upregulated by Rai1 overexpression by differential p-value and fold change are shown in Table 
3. 
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Table 2: Top downregulated genes in Rai1+/- mice. Genes were identified using differential expression p-values and ranked fold 
change.  Functional information from Entrezgene, RefSeq, and Ingenuity. 
Gene 
Symbol 
Differential 
p-value 
fold change Gene Name Functions Associated Phenotypes/Functions 
HOXA5 <.0001 -223.2415 homeobox A5 chr7 Transcription Factor Tumorigenesis 
HOXB6 <.0001 -109.6210 homeobox B6 chr17 Transcription Factor Embryonic development 
GH <.0001 -82.7727 Growth Hormone 
chr17 somatotropin/ 
prolactin hormone 
Growth, obesity, dwarfism, metabolic 
disorder,  hypercholesterolemia 
PCP2 <.0001 -75.9074 Purkinje cell protein 2 chr19 GTPase activator Purkinje cell degeneration 
PRL <.0001 -36.0794 Prolactin chr6 Cytokine hormone 
Glucocorticoid Receptor Signaling, 
hyperinsulinemia 
HOXB5 <.0001 -17.3255 homeobox B5 chr17 Transcription Factor Lung and gut development 
SLC22A6 <.0001 -15.0388 
solute carrier family 22 
member 6 
chr11 Membrane 
Transporter 
Sodium-independent organic anion 
transport 
PRG4 <.0001 -12.3189 proteoglycan 4 chr1 Proteoglycan 
Elastic absorption and energy dissipation of 
synovial fluid 
SLC6A12 <.0001 -7.1673 
solute carrier family 6, 
member 12 
chr12 Neurotransmitter 
GABA receptor signaling, epilepsy, 
generalized anxiety disorder, 
POMC <.0001 -5.2112 propiomelanocortin chr2 Hormone precursor 
Steroidgenesis, pain and energy 
homeostasis, melanocyte stimulation, and 
immune modulation 
EN1 <.0001 -4.8849 engrailed homeobox 1 chr2 Transcription Factor Development: segmentation 
MYOC <.0001 -4.3210 myocilin 
chr1 Glucocorticoid-
inducible response protein 
Cytoskeletal function, regulation of 
intraocular pressure 
DPP4 0.0022 -4.2198 dipeptidyl- peptidase 4 
chr2 Membrane 
glycoprotein 
Cleavage of X-proline dipeptides, diabetes, 
hyperinsulinemia, obesity 
IRX2 <.0001 -3.6987 iroquois homeobox 2 chr5 Transcription Factor Embryonic development 
SLC38A5 0.0017 -3.2475 
solute carrier family 38, 
member 5 
chrX Amino acid 
transporter 
Na-coupled transport of neutral amino 
acids, mental retardation 
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Table 3: Upregulated genes in Rai1-Tg mouse hypothalamus. Genes were identified using differential expression p-values and 
ranked fold change.  Functional information from Entrezgene, RefSeq, and Ingenuity 
 
Differential 
Gene 
 P-val 
Fold 
Change 
Name Function Associated Phenotypes/Functions 
GH <.0001 71.3 Growth Hormone chr17 somatotropin/ 
prolactin hormone 
Growth, obesity, dwarfism, metabolic disorder,  
hypercholesterolemia 
LHB <.0001 68.39 luteinizing hormone beta 
polypeptide 
chr19 glycoprotein hormone Spermatogenesis and ovulation, obesity 
PRL <.0001 62.86 Prolactin chr6 Cytokine hormone Glucocorticoid Receptor Signaling, 
hyperinsulinemia 
TSHB <.0001 33.03 thyroid stimulating 
hormone, beta 
chr1 pituitary hormone cell-cell signaling, anatomical structure 
morphogenesis, response to vitamin A 
CGA <.0001 28.64 glycoprotein hormones, 
alpha polypeptide 
chr6 Glycoprotein Hormone Thyroid hormone signaling, obesity 
HOXB7 <.0001 23.62 homeobox B7 chr17 transcription factor Tumorigenesis 
POMC <.0001 4.17 propiomelanocortin chr2 Hormone precursor Steroidgenesis, pain and energy homeostasis, 
melanocyte stimulation 
AP2B1 <.0001 2.39 adaptor-related protein 
complex2, beta 1 subunit 
chr17 subunit of adapter 
protein 2 
Clathrin linkage to receptors in coated vesicles 
GRID2IP <.0001 2.39 glutamate receptor, 
ionotropic, delta 2 
interacting protein 
chr 7 Control of GRID2 glutamate recpetor in 
purkinje cells, purkinje cell degeneration 
TNNT1 <.0001 2.24 troponin T type 1 chr19 component of 
troponin 
Heart failure, myopathy 
PRKCD <.0001 2.11 protein kinase C, delta chr3 Protein kinase C family B cell signaling, growth, tumorigenesis 
ACTB <.0001 2.09 actin, beta chr7 actin contractile apparatus and nonmuscle 
cytoskeletal actin 
CHMP4B <.0001 2.01 chromatin modifying 
protein 4B 
chr chromatin-modifying 
protein 
MVB formation, cell cycle, cataract 
RREB1 <.0001 1.81     ras responsive element 
binding protein1  
Chr6 transcription factor cancer 
DCTN1 <.0001 1.77 dynactin 1 Chr2 subunit of dynactin interaction with  dynein intermediate chain 
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Gene Expression Patterns Dependant on Rai1 Dosage.  Rai1+/- and Rai1-Tg mice have 
dosage related Rai1 expression patterns in the hypothalamus- the Rai1+/- mouse 
hypothalamus exhibits reduced Rai1 expression compared to wild-type, while the Rai1-Tg 
mouse hypothalamus shows elevated expression.  These expression patterns allow us to 
identify which genes may be affected by Rai1 dosage.  
 Using a differential p-value stringency of .05, 36 genes are underexpressed when 
Rai1 is underexpressed and overexpressed when Rai1 is overexpressed (Fig. 11).  Using 
the same stringency, 2 genes, SGK and RBM3 are overexpressed when Rai1 is 
underexpressed and underexpressed when Rai1 is overexpressed (Fig. 11).  
 
Obesity Genes.  Considering the obese phenotype observed in Rai1+/- mice and SMS 
individuals, we looked at genes related to an obese phenotype.  Using Ingenuity software 
analysis for disease and phenotype, we found 20 genes associated with obesity that were 
differentially expressed in either Rai1-Tg or Rai1+/- mouse hypothalamus (Fig. 12).  
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Figure 11: Heat map of genes affected by Rai1 dosage. Most genes shown have a direct 
dosage relationship with Rai1.  SGK and RBM3 have an inverse dosage relationship with 
Rai1.  All genes have a differential p-value of <.05.  
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Figure 12: Heat map of obesity related gene expression.  All genes have a significant 
differential p-value from WT mice.  Obesity function was determined using Ingenuity 
disease phenotypes and Entrez Gene entries.  
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Phenotypic Pathways.  Ingenuity Pathway Analysis software was used to determine 
which biological pathways involved genes differentially expressed in Rai1+/- and Rai1-Tg 
mice.  A p-value for each pathway was determined using Fisher’s exact tests to determine 
the likelihood of those genes assigned by chance. Biological pathways altered in Rai1+/- 
mice include psychological disorders and behavior (Adbr2, Ap2b1, Arrb1, Bdnf, Btrc, 
Crhr2, Dleu2, Ednra, Etv5, Gtf2h4, Hist1h2bj, Isg15, Kcnk2, Mthfd1, Npy, Pes1, Ripk4, 
Rras, Slc16a6, Sytl4, Tnfaip8, Tnfrsf19, Traf2, Ucn)(Fig. 13) and neurological 
development (Aebp1, Bdnf, Fgfrl1, Fndc5, Kif17, Leng8, Mkks, Ncan, Olfml3, Prkcsh, 
Ptprs, Sgk1,Srr, Trhde, Ube2e3) (Fig. 14).  
Biological pathways altered in Rai1-Tg mice include Development, Behavior, and 
Digestion (Bzrap1, Cck, Ckbr, Cebpg, Dbi, Ddit3, Dlk1, Dmap1, Dnttip1, Epc1, Fosl2, 
Grn, Hsf4, Insig1, Mark2, Mmp17, Pmch, Prkch, Ptprz1, Rgs3, S100a1, Sh2b3, Slc12a6, 
Slc5a5, Tacc1, Trio, Uba5, Yeats4, Znhit1)(Fig. 15) and DNA Replication and Repair 
(Actb, Akap8l, Banf1, Coro2b, Eif1ax, Eif3eip, Eif4a2, Eif4a3, Eif4g1, Emd, Ensa, 
Hsd11b1, Igf2, Insulin, Ogn, Pde, Pde1a, Pde1b, Pde4a, Plagl2, Ran, Rpl10, Rpl15, 
Rpl18, Rps6, Rps7, Rps8, Rps1g, Sez6l2, Stau1, Stxbp4, Syne1, Vrk3, Znrd1) (Fig. 16).  
 
Confirmation of expression using qRT-PCR.  Using Ingenuity pathway analysis 
software, we selected three genes which were associated with satiety and differentially 
expressed for confirmation using qPCR: Cholecystokinin (Cck), brain-derived 
neurotrophic factor (Bdnf), and neuropeptide Y (Npy).  Each gene was confirmed using 
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RNA from 4 Rai1+/- mice, 6 wild-type controls, and 3 Rai1-Tg mice (Fig. 17).  There 
were no differences between male or female expression.  
  Cholecystokinin (Cck) is a brain/gut peptide involved in satiety that regulates food 
intake and weight gain 76, 77.  It can decrease the expression levels of Npy, which are 
usually colocalized with Cck in the neurons of the arcuate nucleus 78.  It can regulate 
ghrelin expression and has a similar effect as the satiety hormone, leptin  79, 80.  Microarray 
data show that Cck was downregulated 1.5 fold in Rai1+/- mice, while upregulated 1.2 
fold in Rai1-Tg mice.  Q-PCR showed a less significant decrease in Rai1+/- mice, but a 
very strong upregulation in Rai1-Tg mice.  
Neuropeptide Y (NPY) is a neurotransmitter located in the neurons of the arcuate 
nucleus of the hypothalamus and plays an important role in the stimulation of hunger.  
Ghrelin activates Npy containing neurons causing an increase in [Ca2+]i via the 
phospholipase C and adenylate cyclase-PKA pathways, while leptin acts as an agonist via 
the phosphatidylinositol 3-kinase-PDE3 pathway 81, 82.  Overexpression of Npy causes an 
increase in feeding and weight gain  83, 84.  Loss of Npy expression has been shown to 
attenuate hyperphagic response to fasting and leptin deficiency  85, 86.  Microarray data 
show that Npy was upregulated 1.6 fold in Rai1+/- mice and not significantly changed in 
Rai1-Tg mice.  Q-PCR showed a less significant increase in Rai1+/- mice, but a strong 
downregulation in Rai1-Tg mice.  
Brain-derived neurotrophic factor (Bdnf) is a neurotrophic growth factor involved 
in the growth of striatal neurons 87.  Reduced expression of BDNF has been identified in 
depression, schizophrenia, and obsessive-compulsive disorder  88, 89, 90, 91, 92, 93.  Local 
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deletion of Bdnf in the ventromedial and dorsomedial hypothalamus was found to induce 
hyperphagia and obesity 49. Haploinsufficiency for Bdnf in mice was found to cause 
increased food intake, early-onset obesity, hyperactivity, and cognitive impairment 94.  
Microarray data show that Bdnf was downregulated 2.5 fold in Rai1+/- mice and 
unchanged in the Rai1-Tg mice.  Q-PCR confirmed the downregulation observed in 
Rai1+/- mice and also showed a positive dosage effect in Rai1-Tg mice.  
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Figure 13: Psychological Disorders and Behavioral Pathway in Rai1+/- mice.  
Ingenuity Created Pathway showing a Psychological and Behavioral Pathway and genes 
which were altered in Rai1+/- mice.  Genes that were differentially expressed from wild-
type in the whole genome microarray have a fold change value listed below the gene name.  
Note the inclusion of confirmed genes BDNF and NPY.  IPA score=39.  
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Figure 14: Nervous System Development and Cell Death Pathway in Rai1+/- mice.  
Ingenuity Created Pathway showing a Nervous System Development and Cell Death 
Pathway and genes which were altered in Rai1+/- mice.  Genes that were differentially 
expressed from wild-type in the whole genome microarray have a fold change value listed 
below the gene name.  Note the inclusion of BDNF.  IPA score=20.  
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Figure 15: Protein Synthesis and DNA Replication Pathway in Rai-Tg mice.  Ingenuity 
Created Pathway showing a Protein Synthesis and DNA Replication Pathway and genes 
which were altered in Rai1-Tg mice.  Genes that were differentially expressed from wild-
type in the whole genome microarray have a fold change value listed below the gene name.  
Note the central role of insulin.  IPA score=41.  
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Figure 16: Development, Behavior, and Digestion Pathway in Rai-Tg mice.  Ingenuity 
Created Pathway showing a Development, Behavior, and Digestion Pathway and genes 
which were altered in Rai1-Tg mice.  Genes that were differentially expressed from wild-
type in the whole genome microarray have a fold change value listed below the gene name.  
Note the inclusion of CCK.  IPA score=34.  
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Figure 17: Confirmation of microarray results.  Q-PCR confirmation of microarray 
results.  Wild-type is set to 1 and the relative expression in Rai1+/- and Rai1-Tg is shown 
in arbitrary units.  Cck is strongly overexpressed in wild-type, but there is no significant 
downregulation in Rai1+/- mice.  Bdnf is downregulated in Rai1+/- mice and seems to 
have a direct relationship to dosage of Rai1.  Npy is downregulated in Rai1-Tg mice, but 
not significantly upregulated in Rai1+/-.  May have an inverse relationship with Rai1 
dosage.  Rai1 expression levels are confirmed and match known genotype expression 
patterns.  Graphs represent mean±SEM. (* p <.05, **p <.01, *** p <.001) 
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DISCUSSION 
We have provided evidence for the role of the hypothalamus in the obesity and 
satiation phenotypes seen in mouse models of SMS and dup(17)(p11.2) syndrome.  A large 
number of genes were differentially expressed in both Rai1+/- and Rai1-Tg mouse 
hypothalami.  Top upregulated and downregulated genes include transcription factors, 
hormones, and neurotransmitters.  Many of the genes found to be differentially expressed 
are associated with obesity.  There were 38 genes that were differentially expressed due to 
Rai1 dosage.  
Thirty-six genes are underexpressed when Rai1 is underexpressed and 
overexpressed when Rai1 is overexpressed.  Some genes were found to have phenotypes 
which relate to those observed in SMS and dup(17)(p11.2) syndrome.  These may warrant 
further confirmation and investigation.  Growth hormone (GH) and prolactin (PRL) are 
associated with growth, but levels within SMS cohorts were identified as being within 
normal levels and following a normal circadian rhythm 95.  Proopiomelanocortin, POMC1, 
has been associated with severe early-onset obesity 96. WNT9B is involved in midfacial 
development.  Knockout mutations of Wnt9b can model cleft lips in mice 97.  Lecithin 
cholesterol acyltransferase, LCAT, regulates cholesterol transport and deficiency in mice 
can cause hepatic overproduction of triglycerides 98.  Gastrulation brain homeobox 2, 
GBX2, is a transcription factor necessary for hindbrain development 99.  Transcription 
factor 7–like 2 gene, TCF7L2, is involved with insulin signaling in the pancreas 100.  
TCF7L2 variants are associated with Type II Diabetes 101.   
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Two genes were found to be downregulated when Rai1 is overexpressed and 
upregulated in Rai1+/-, Sgk and Rbm3.  SGK, serum- and glucocorticoid-dependent protein 
kinase, is involved in mediating the epithelial sodium channel and glucose transport in the 
kidneys 102.  It is also activated by insulin and involved in the regulation of insulin 
secretion 103, 104.  Recent findings indicate that SGK is involved in energy homeostasis. 
SGK expression is high in conditions of hyperphagia, weight gain, or fasting, while low in 
conditions of energy storage 105.  Considering that Rai1-Tg are hypoinsulinemic and 
Rai1+/- mice have hyperphagia induced obesity, the role of Sgk  in Rai1 mice warrants 
further study.  RBM3, RNA binding motif protein 3, is a cold-stress induced shock protein 
and a global transcription regulator 106.  Like Rai1, RBM3 localizes to the neuronal rich 
areas of the brain and is not found in the corpus callosum 107.  The dosage model of Rbm3 
observed in Rai1 mice is inverse to the dosage of Rai1.  Further investigation is needed to 
determine if this is a compensatory response to low Rai1. 
 Confirmation of Cck, Npy, and Bdnf demonstrate which satiety genes in the mouse 
hypothalamus contribute to the obesity phenotype in Rai1+/- mice.  Cck is likely not 
causative of the hyperphagia observed in Rai1+/- mice.  However, overexpression of Cck 
has been linked to renal abnormalities and could be investigated in the kidneys of Rai1-Tg 
mice.  Npy expression shows a slight dosage related effect and might cause a compensation 
of PYY, which was elevated in Rai1+/- serum.  Bdnf may be causative of the hyperphagia 
and obesity seen in Rai1+/- mice.   
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CHAPTER 5: Discussion 
 
 
We have provided evidence that Rai1 dosage affects feeding and satiety, with 
involvement of hypothalamic satiety pathways.  We have also shown that Rai1 dosage 
affects fat deposition patterns and female visceral fat in mice and humans.    
Rai1-Tg mice are not hyperphagic but have decreased insulin levels.  Many genes 
differentially expressed in these mice are involved in insulin secretion.  The pathogenic 
effects of hypoinsulinemia have not been characterized in Rai1-Tg mice and should be 
investigated.  Pathology of the pancreas, liver, adipose tissues, and kidneys may reveal 
physical abnormalities that affect insulin secretion in these mice.  Tissue pathology is of 
particular interest considering the excess of growth hormone seen in the microarray data.  
Previous studies indicate that growth hormone has tissue specific effects on insulin 
secretion and sensitivity 108, 109.  These mice, in addition to leading to a greater 
understanding of dup(17)(p11.2) syndrome, may also further characterize the role of 
growth hormone in diabetes.  
Rai1+/- mice are hyperphagic and obese.  These data seem to model the 
hyperphagia and obesity seen in humans.  Many of these tests, particularly feeding tests, 
were limited by the availability of age and sex matched Rai1+/- mice.  As more mice 
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become available, replications of previous studies are necessary.  Rai1+/- consume more 
food during the rest cycle, which may indicate more dramatic changes in circadian rhythm 
than has previously been shown in wheel studies.  Infrared light analysis may provide 
better insight into the circadian rhythm and levels of light phase activity in these mice.  
Some reports indicate that SMS patients seem to hoard and seek out salty foods  31.  Food 
preference tests may be done to determine a potential genetic basis for this behavior.  The 
metabolic rate and energy expenditure of Rai1+/- mice can be measured using an indirect 
calorimetry metabolism chamber.  A better understanding of the metabolic phenotypes and 
feeding behaviors in these mice will lead to better understanding of obesity in SMS and 
genetic effects on energy homeostasis.   
In addition to confirming studies in mice, hyperphagia can be better understood in 
SMS patients.  Familial and anecdotal evidence suggests night eating and food hoarding in 
SMS may be discouraged by locking up kitchens and cabinets.  However, this information 
was not found in the available literature.  Confirming these data using a caretaker study, 
similar to the survey on truncal obesity, will lead to a greater understanding of SMS 
behaviors which may contribute to obesity.  
RAI1 affects adiposity when overexpressed or underexpressed.  However, there is 
no conclusive evidence of the pathogenecity associated with increased visceral fat in these 
mice.  Comorbidities that should be assessed include cardiovascular risk, blood pressure, 
and metabolic syndrome.  There is strong evidence that these comorbidities of visceral 
obesity are also affected by alterations in the circadian cycle.  Myocardial cells and 
adipocytes have a circadian cycle, and  Clock mutant mice have an altered circadian 
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rhythm and muted 24 hr cycle in systolic and diastolic blood pressures 110.  These mice also 
have cardiovascular disease 50.  Evaluating blood pressure and changes in the expression 
levels in the hearts of Rai1 mice may reveal the downstream effects of the observed 
adiposity changes on cardiovascular health, as well as the relationship between the 
circadian cycles and obesity comorbidities.  
Rai1-Tg females and Rai1+/- females have an increased proportion of visceral fat 
when compared to wild-type mice.  Increased visceral fat deposition is seen in females 
with polycystic ovary syndrome, an endocrine-metabolic disorder that results in increased 
risk for infertility, obesity, metabolic syndrome, cardiovascular disease 112,113.  Evaluation 
of serum hormones in Rai1-Tg and Rai1+/- mice can be used to determine if Rai1 affects 
sex hormone levels.   
Further studies are needed to determine the implications of increased obesity and 
metabolic changes in these mice.  Fat expression and secretion studies may be useful in 
determining altered levels of adipokines in Rai1 mice.  Considering the observed increase 
in abdominal fat in Rai1-Tg and Rai1+/- females, these mice may be used to determine the 
risks of visceral obesity in SMS patients and lead to a more comprehensive understanding 
of the pathogencity of visceral fat in females in the general population.  
Microarray analysis successfully identified changes in satiety genes (Npy and Bdnf) 
in Rai1 mice and demonstrated altered expression of Rai1 in the hypothalamus.  This study 
was limited in scope to genes related to satiety and obesity, but these data can be used to 
identify genes related to observed hypoinsulinemia, cognitive dysfunction, and altered 
molecular mechanisms.  Of particular interest are the many genes involved in behavior and 
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psychological disorders.  Considering the severe impact of the behavioral phenotypes on 
the quality of life of SMS patients, these data may be useful in identifying how cognitive 
function is altered in a complex disorder.  Rai1+/- mice also underexpress Bdnf in the 
hypothalamus, which has been shown to cause obesity.  BNDF is a neurotropic factor 
which can affect serotonergic neurotransmission 111.  Considering the overlapping 
behavioral phenotypes of BDNF haploinsufficiency and RAI1 haploinsufficency, as well as 
the changes in the melatonin pathway in SMS, comprehensive analysis of the role to 
serotonin uptake and regulation should be studied in these mice.  BDNF expression could 
also be characterized in SMS human cells to clarify the role of BDNF in SMS.  
In addition to a more comprehensive understanding of SMS and dup(17)(p11.2) 
syndrome, the data presented in these studies are precursory to a greater characterization of 
the role of RAI1 in growth, obesity, adiposity, and behavior.  
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APPENDIX  
 
PATIENT GROWTH SURVEY 
Consent: 
• The purpose of this study is to better characterize growth and metabolism in 
chromosome 17 disorders (including Smith-Magenis syndrome (SMS) and 
duplication 17p11.2 syndrome (Potocki-Lupski syndrome). 
• In this study, you will be asked to complete a brief online survey about your child’s 
weight and body type.  You may not get any direct benefit from this survey, but the 
information we learn in this survey may help us better understand and provide care 
for children with 17p disorders.  
• If you do not have online access or would prefer to complete the questionnaire by 
mail or email, please contact:  Brooke Burns, Study Coordinator at (804)628-1631 
or by email at burnsbm@vcu.edu 
• There are no costs for participating in this survey other than the time you will spend 
filling out the questionnaire.  
• You will receive an opportunity to win a $100 Amazon.com gift card if you 
provide an email address when you complete the questionnaire.  Winners will be 
chosen by random drawing. 
• The questionnaire is anonymous and access to all data will be limited to study 
personnel.  A data and safety monitoring plan is established.  What we find from 
this survey may be presented at meetings or published in papers, but neither your 
name nor your child’s name will be used in these presentations or papers. 
• You do not have to participate in this survey.  If you choose to participate, you may 
stop at any time without any penalty. 
  
I have been given the chance to read this consent information.  I understand the 
information about this survey.  Completion of this survey indicates that I am willing to 
participate. 
 
Questionnaire:  
 
My child has been diagnosed by a geneticist with:   
 
1.  Smith-Magenis syndrome, del(17)(p11.2)  
2. Smith-Mageni syndrome, RAI1 mutation 
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3.  Potocki-Lupski syndrome, dup(17)(p11.2)  
4.  My child has not been diagnosed by a geneticist.  
 
5.   Current weight of child   _____ kg or ______ lbs.  
6.   Current height of child   ______cm or ______ in.  
7. Current age of child _______ years 
8.  My son/daughter is _______male _______female 
 
 
Email address to receive notification of gift card: _________________________ 
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9. Please select the single description that best matches your child’s body type:  
 
A.            My son/daughter tends to store extra weight on 
arms, legs, hips, and buttocks.  Very little weight is stored 
around the waist.  
 
 
 
 
 
 
 
 
 
 
B.  My son/daughter tends to store extra weight around 
waist and stomach areas.  Very little is stored around the legs 
and buttocks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
C.  My son/daughter stores weight evenly throughout 
body- over stomach, arms, legs, and buttocks. 
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D. My son/daughter is very thin and has no excess weight.  Veins are visible through skin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.   My son/daughter has a lot of excess weight that is 
distributed throughout the stomach, arms, legs, and hips.   
 
 
 
 
 
 
 
 
 
 
 
 
 
F.    My son/daughter carries a lot of excess weight in the 
stomach.  Very little weight is stored around   hips, arms, and 
legs.  Legs may be very thin. 
 
 
 
 
 
